HK1199409A1 - 結合磷酰膽碱 和/或 結合物的抗體 - Google Patents

結合磷酰膽碱 和/或 結合物的抗體

Info

Publication number
HK1199409A1
HK1199409A1 HK14113055.9A HK14113055A HK1199409A1 HK 1199409 A1 HK1199409 A1 HK 1199409A1 HK 14113055 A HK14113055 A HK 14113055A HK 1199409 A1 HK1199409 A1 HK 1199409A1
Authority
HK
Hong Kong
Prior art keywords
phosphorylcholine
conjugates
antibodies binding
antibodies
binding
Prior art date
Application number
HK14113055.9A
Other languages
English (en)
Inventor
.彼得松
.坎貝爾
丹.塞克斯頓
安德魯.
.尼克松
Original Assignee
Athera Biotechnologies Ab
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab, Dyax Corp filed Critical Athera Biotechnologies Ab
Publication of HK1199409A1 publication Critical patent/HK1199409A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK14113055.9A 2011-08-09 2014-12-30 結合磷酰膽碱 和/或 結合物的抗體 HK1199409A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161521607P 2011-08-09 2011-08-09
PCT/US2012/049990 WO2013022968A1 (en) 2011-08-09 2012-08-08 Antibodies binding to phosphorylcholine (pc) and/or pc conjugates

Publications (1)

Publication Number Publication Date
HK1199409A1 true HK1199409A1 (zh) 2015-07-03

Family

ID=47668922

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14113055.9A HK1199409A1 (zh) 2011-08-09 2014-12-30 結合磷酰膽碱 和/或 結合物的抗體

Country Status (8)

Country Link
US (3) US9796786B2 (zh)
EP (1) EP2741770A4 (zh)
JP (1) JP6277126B2 (zh)
CN (1) CN103906532B (zh)
AU (1) AU2012294431B2 (zh)
CA (1) CA2843960C (zh)
HK (1) HK1199409A1 (zh)
WO (1) WO2013022968A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2014009344A (en) 2011-08-09 2014-07-30 Athera Biotechnologies Ab New antibodies against phosphorylcholine
JP6277126B2 (ja) * 2011-08-09 2018-02-07 アセラ・バイオテクノロジーズ・アーベー ホスホリルコリン(pc)および/またはpcコンジュゲートに結合する抗体
WO2014131034A2 (en) * 2013-02-25 2014-08-28 The Regents Of The University Of California Antibodies to oxidized phospholipids
WO2016115559A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2017136607A1 (en) 2016-02-02 2017-08-10 Fred Hutchinson Cancer Research Center Anti-ror1 antibodies and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402664A1 (fr) 1977-09-07 1979-04-06 Agronomique Inst Nat Rech Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications
US5955584A (en) 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
DE3751182T2 (de) 1986-08-06 1995-10-26 Scripps Clinic Res Monoklonale Antikörper, B-spezifisch für Apolipoprotein, die von zwei Hybridomen erzeugt werden.
JPH02188532A (ja) 1989-01-17 1990-07-24 Otsuka Pharmaceut Co Ltd リポソームワクチン
AU5522390A (en) 1989-04-19 1990-11-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids
JP3283041B2 (ja) 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
WO1992010203A1 (en) 1990-12-10 1992-06-25 Alving Carl R A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis
CA2131150A1 (en) 1992-03-03 1993-09-16 Michel C. Nussenzweig Receptor complexes with b29 (ig-beta or ig-gamma) and their uses
AU5959494A (en) 1992-12-29 1994-07-19 Entremed, Inc Vaccines against sterols
CA2151742C (en) 1993-02-22 1999-05-25 Alfred A. Amkraut Compositions for oral delivery of active agents
US5455032A (en) 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
AU1159497A (en) 1996-11-08 1998-06-03 Regents Of The University Of California, The Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6375925B1 (en) 1996-11-08 2002-04-23 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US20040185039A1 (en) 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
DK1095271T3 (da) 1998-07-03 2003-12-15 Athera Biotechnologies Ab Fremgangsmåde til diagnose af hjertekar-sygdomme og tidlig aterosklerose
ATE506615T1 (de) 1999-10-26 2011-05-15 Univ California Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
AU2001259730A1 (en) 2000-05-12 2001-11-26 The Regents Of The University Of California Standardized oxidized ldl assay
CA2407910C (en) * 2000-06-16 2013-03-12 Steven M. Ruben Antibodies that immunospecifically bind to blys
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20070122419A1 (en) 2003-04-11 2007-05-31 The Regents Of The University Of California Methods and compositions for treating atherosclerosis
CA2776927C (en) 2004-04-15 2014-08-12 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
US7329737B2 (en) 2004-08-03 2008-02-12 Dyax Corp. Antibodies that bind hK-1
JPWO2006028162A1 (ja) 2004-09-08 2008-05-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 シグナルプローブポリマーの形成方法
WO2006110831A2 (en) 2005-04-12 2006-10-19 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20080311122A1 (en) 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
WO2008150485A2 (en) 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
JP5122908B2 (ja) 2007-10-17 2013-01-16 日泉化学株式会社 自動車の内装用部材の取り付け構造
WO2010003602A1 (en) 2008-07-07 2010-01-14 Athera Biotechnologies Ab New therapeutic and diagnostic methods for alzheimer's disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
SG2014009344A (en) 2011-08-09 2014-07-30 Athera Biotechnologies Ab New antibodies against phosphorylcholine
JP6277126B2 (ja) * 2011-08-09 2018-02-07 アセラ・バイオテクノロジーズ・アーベー ホスホリルコリン(pc)および/またはpcコンジュゲートに結合する抗体

Also Published As

Publication number Publication date
AU2012294431A1 (en) 2014-02-20
CN103906532B (zh) 2018-01-26
JP6277126B2 (ja) 2018-02-07
US9796786B2 (en) 2017-10-24
US20210230310A1 (en) 2021-07-29
CA2843960A1 (en) 2013-02-14
JP2014529398A (ja) 2014-11-13
AU2012294431B2 (en) 2017-03-30
EP2741770A1 (en) 2014-06-18
CA2843960C (en) 2020-09-15
CN103906532A (zh) 2014-07-02
US20180086847A1 (en) 2018-03-29
US20140193413A1 (en) 2014-07-10
EP2741770A4 (en) 2014-12-31
WO2013022968A1 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
IL271804A (en) Mice producing binding proteins containing VL domains
HUS1900048I1 (hu) Anti-IL-23 antitestek
ZA201304905B (en) TNF-a BINDING PROTEINS
SG10201401681PA (en) Novel antigen binding proteins
IL222980A0 (en) Il-1 binding proteins
ZA201209004B (en) Anti-fgfr2 antibodies
ZA201208906B (en) Humanised antigen binding proteins to myostatin6
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
ZA201205624B (en) Cd127 binding proteins
HK1194388A1 (zh) 抗缺刻蛋白 抗體
PL2603528T3 (pl) Przeciwciała Fab-glikozylowane
GB201020738D0 (en) Antibodies
GB201002238D0 (en) Antibodies
HUE036251T2 (hu) Kitinféle poliszacharid antigént kötõ fehérjék
IL225571A0 (en) Antibodies
IL226157A0 (en) Antigen binding proteins
HK1199409A1 (zh) 結合磷酰膽碱 和/或 結合物的抗體
GB201016809D0 (en) Improvements in relation to antibody binding
GB201020751D0 (en) Antibodies
GB201005062D0 (en) Antibodies

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220805